Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Human Pathology|November 29, 2015
Concordance study between one-step nucleic acid amplification and morphologic techniques to detect lymph node metastasis in papillary carcinoma of the thyroidSofía del Carmen, Sonia Gatius, Guzmán Franch-Arcas, et al.
Nature Neuroscience|October 24, 2007
Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsyDavid Vilchez, Susana Ros, Daniel Cifuentes, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 26, 2019
Magnetic detection of sentinel lymph node in papillary thyroid carcinoma: The MAGIC-PAT study resultsJuan Antonio Baena Fustegueras, Fernando Herrerías González, Sònia Gatius Calderó, et al.
Science Signaling|February 27, 2024
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradationEmily C Erickson, Inchul You, Grace Perry, et al.
Human Molecular Genetics|November 22, 2007
Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathwayMaria Carmen Solaz-Fuster, José Vicente Gimeno-Alcañiz, Susana Ros, et al.
NPJ Breast Cancer|April 22, 2025
The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancerValentina Cutano, Ming Li Chia, Eleanor M Wigmore, et al.
NPJ Breast Cancer|August 5, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Cancer Cell|September 25, 2020
Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast CancerSusana Ros, Alan J Wright, Paula D'Santos, et al.
Minerva Endocrinology|December 12, 2025
Recurrence factors in familial papillary thyroid carcinomaAntonio Ríos, Iñaki Amunategui, José Ruiz Pardo, et al.
Molecular Cancer Therapeutics|April 15, 2026
Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancerValentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, et al.
Pageof 5